Synlogic publishes papers in nature journals demonstrating proof-of-mechanism and potential of synthetic biotic platform for the treatment of phenylketonuria (pku)

Cambridge, mass., july 22, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the publication of two papers in the journals nature metabolism and communications biology.
SYBX Ratings Summary
SYBX Quant Ranking